Mecolzup (Mesalazine)

Mesalazine exerts its effect by inhibiting cyclooxygenase and lipoxygenase enzymes in the colonic mucosa, which lowers prostaglandin and leukotriene production. It also scavenges free radicals, decreasing oxidative stress and limiting the activation of inflammatory cells, thereby reducing mucosal inflammation.

The dosage of Mecolzup is determined by the prescribing clinician based on the severity of disease, patient weight, and response to therapy. Healthcare professionals tailor the regimen to each individual, and patients should follow the specific instructions provided by their prescriber.

Safety data for mesalazine in pregnancy are limited, so the benefits and risks should be evaluated by a healthcare professional. During breastfeeding, the drug may be excreted in milk; clinicians usually consider the therapeutic need versus potential exposure to the infant before recommending use.

To place an order, submit an enquiry on the Mecolzup product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mecolzup delivers mesalazine directly to the rectum, offering a targeted anti‑inflammatory effect with minimal systemic exposure compared with oral 5‑ASA formulations. This can result in fewer systemic side effects, but it is limited to distal disease. Other options, such as oral mesalazine or biologics, may be chosen for extensive colitis or refractory cases.

Mecolzup should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mecolzup is a rectal formulation that is inserted into the rectum using the supplied applicator or an appropriate enema device. The patient should follow the prescriber’s instructions regarding frequency and position (often lying on the left side) to ensure optimal distribution of the medication.

Serious risks include severe allergic reactions such as rash, swelling or anaphylaxis, and worsening of colitis symptoms, which may present as increased bleeding or abdominal pain. Rarely, mesalazine can cause liver enzyme elevations, pancreatitis, or blood dyscrasias, all of which require immediate medical attention.

Mecolzup should be avoided in individuals with a known hypersensitivity to mesalazine, other 5‑ASA compounds, or salicylates. Patients with severe renal impairment, active severe ulcerative colitis requiring systemic therapy, or those taking interacting medications without proper monitoring should not use this product without medical guidance.